Next Article in Journal
The Vascular Side of Chronic Bed Rest: When a Therapeutic Approach Becomes Deleterious
Previous Article in Journal
Deproteinization as a Rapid Method of Saliva Purification for the Determination of Carbamazepine and Carbamazepine-10,11 Epoxide
Previous Article in Special Issue
Statin and Cancer Mortality and Survival: An Umbrella Systematic Review and Meta-Analysis
Article

Assessment of the Efficacy of Lowering LDL Cholesterol with Rosuvastatin 10 mg in Four Korean Statin Benefit Groups as per ACC/AHA Guidelines (NewStaR4G)

1
Division of Cardiology, Department of Internal Medicine, Ewha Womans University Medical Center, Ewha Womans University School of Medicine, Seoul 07985, Korea
2
Division of Cardiology, Department of Internal Medicine, Yonsei University, Wonju Severance Christian Hospital, Wonju 26426, Korea
3
Division of Cardiology, Department of Internal Medicine, Seoul Medical Center, Seoul 02053, Korea
4
Bundang Cha Hospital Cardiovascular Center, Seongnam 13496, Korea
5
Seoul National University Bundang Hospital, Seoul National University School of Medicine, Seongnam 13620, Korea
6
Inje University Ilsan Paik Hospital Cardiology, Goyang 10380, Korea
7
Heart Research Institute Chung-ang University Hospital, Seoul 06973, Korea
8
Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Korea
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(4), 916; https://doi.org/10.3390/jcm9040916
Received: 16 March 2020 / Revised: 24 March 2020 / Accepted: 25 March 2020 / Published: 27 March 2020
(This article belongs to the Special Issue Current and Emerging Uses of Statins in Clinical Therapeutics)
The American College of Cardiology and American Heart Association (ACC/AHA) guidelines identified four statin benefit groups on the basis of atherosclerotic cardiovascular disease risk reduction and proposed statin therapy by evidence-based intensity. Although these guidelines used randomized controlled trials with hard outcomes as exclusive evidence for its recommendations, a limited number of studies conducted in Asian countries makes its application of treatment strategy, intensity, and statin doses uncertain in these population. This prospective, multicenter study aimed to evaluate the efficacy of rosuvastatin 10 mg in the four statin benefit groups requiring high- or moderate-intensity statin therapy according to the ACC/AHA guidelines in the Korean population. The primary endpoint was percentage reduction in low-density lipoprotein (LDL) cholesterol. Secondary endpoints were percentage reduction in other lipids and achievement of ≥50% reduction in LDL cholesterol. Rosuvastatin 10 mg lowered LDL cholesterol by 61.4 mg/dL, a 44.9% decrease from baseline after eight weeks. Reduction of LDL cholesterol ≥50% was achieved in 46.3% of patients. Rosuvastatin 10 mg was generally well tolerated. In the Korean population, rosuvastatin 10 mg was favorable and tolerant in lowering LDL cholesterol in the four statin benefit groups requiring high- or moderate-intensity statin therapy according to the ACC/AHA guidelines. View Full-Text
Keywords: Rosuvastatin; cholesterol; LDL; Asian Rosuvastatin; cholesterol; LDL; Asian
Show Figures

Figure 1

MDPI and ACS Style

Kim, K.-J.; Yoon, J.; Won, K.H.; Lim, S.-W.; Chae, I.-H.; Lee, S.Y.; Kim, S.-W.; Kim, H.-S. Assessment of the Efficacy of Lowering LDL Cholesterol with Rosuvastatin 10 mg in Four Korean Statin Benefit Groups as per ACC/AHA Guidelines (NewStaR4G). J. Clin. Med. 2020, 9, 916. https://doi.org/10.3390/jcm9040916

AMA Style

Kim K-J, Yoon J, Won KH, Lim S-W, Chae I-H, Lee SY, Kim S-W, Kim H-S. Assessment of the Efficacy of Lowering LDL Cholesterol with Rosuvastatin 10 mg in Four Korean Statin Benefit Groups as per ACC/AHA Guidelines (NewStaR4G). Journal of Clinical Medicine. 2020; 9(4):916. https://doi.org/10.3390/jcm9040916

Chicago/Turabian Style

Kim, Kyung-Jin, Junghan Yoon, Kyung H. Won, Sang-Wook Lim, In-Ho Chae, Sung Y. Lee, Sang-Wook Kim, and Hyo-Soo Kim. 2020. "Assessment of the Efficacy of Lowering LDL Cholesterol with Rosuvastatin 10 mg in Four Korean Statin Benefit Groups as per ACC/AHA Guidelines (NewStaR4G)" Journal of Clinical Medicine 9, no. 4: 916. https://doi.org/10.3390/jcm9040916

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop